The infusion of non-cryopreserved allogeneic BM is usually well tolerated. If infusion-related complications do occur, they are generally mild. In one study of 71 patients, the only reported side effects were nausea (14%), vomiting (8.5%) and chills (1.4%). 1 In a smaller study with fifteen patients, only one (6%) experienced mild side effects. 2 Despite infusion of seventeen BM autografts and allografts contaminated with common skin bacteria, no immediate toxicity developed in the recipients. 3 In rare instances, serious events such as transfusion-related acute lung injury occur. 4 We report prolonged bleeding in a transplant recipient caused by heparin added to the donor's harvested BM.
A 47-year-old diabetic woman, weighing 90.5 kg, with no previous history of abnormal bleeding was diagnosed with acute myelogenous leukemia (subtype M2). She was treated with two courses of cytarabine 3 g/m 2 every 12 h on days 1-6 and idarubicin 12 mg/m 2 on days 1-3 and achieved a CR after the first course. She subsequently received a myeloablative matched-sibling BMT after conditioning with fludarabine and BU. A total of 930 ml of BM anticoagulated with heparin sodium was infused over 84 min. Because of diabetes mellitus, her glucose was checked by the finger-stick method 90 min after the marrow infusion was completed. She bled continuously from the finger-stick for a total of 4 h.
The addition of 10-20 U of heparin per ml of harvested allogeneic BM is a standard practice. 5, 6 In the original paper by Thomas and Storb, 7 the total amount of preservative-free unfractionated heparin used, albeit with tissue culture medium (TC-199), ranged from 2000 to 9200 U (11.5-23.7 U/ml of marrow). The paucity of literature on immediate post-infusion bleeding and laboratory monitoring by activated partial thromboplastin time (aPTT) not only suggests that anticoagulation of BM is well tolerated from a hemostatic standpoint but also that the incidence of heparin toxicity is not well established.
Nonlinear heparin kinetics (by aPTT and anti-Xa methods) have been described in normal human subjects. 8 There is a fast initial removal phase lasting about 10-15 min, followed by a dose-dependent convex elimination curve lasting several hours. Subjects in this study received large single i.v. doses of heparin (75, 150 and 250 U/kg), which were eliminated in approximately 4, 6 and 8 h, respectively.
Our patient received 26 000 U (287 U/kg) of heparin. This dose was calculated in order to achieve a final concentration of 20 U of heparin per ml in a projected volume of 1300 ml of BM. Eight-hundred milliliters of BM harvest were added to 130 ml of Plasma-Lyte A solution containing 200 U/ml of heparin (Heparin sodium injection 5000 U USP/ml APP (McKesson)). Less volume of marrow was harvested than initially projected because of a high yield of mononuclear cells. The aPTT remained prolonged for at least 11 h after infusion due to the higher dose of heparin (Table 1) . During the bleeding phase, there was no appreciable decrement in the platelet count, which remained above 150 Â 10 9 /l. Since the dose of heparin infused is directly related to the marrow volume, large volume infusions in small patients are more likely to result in heparin toxicity.
To our knowledge, this is the first report of prolonged bleeding following allogeneic BM infusion. This finding has several important clinical implications. First, potentially life-threatening spontaneous hemorrhage may occur in the initial 12 h after infusion and should be immediately reversed with protamine sulfate (50 mg i.v. bolus). The increased risk of bleeding with boluses of heparin is well documented.
9,10 Second, non-emergency invasive procedures (including needle sticks) should be delayed for at least 8-12 h post infusion. Venous glucose monitoring may be preferable to finger-stick during the early post-infusion period. If an invasive procedure must be performed, aPTT monitoring is necessary. Third, because a higher than usual dose of heparin (28 U/ml of BM) appears to have contributed to bleeding in this case, use of a lower final concentration (15 U/ml) or individualized weight-based calculation may prevent this problem. Alternatively, 
